Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1996 Jan;40(1):55–60. doi: 10.1128/aac.40.1.55

Efficacy of vancomycin and teicoplanin alone and in combination with streptomycin in experimental, low-level vancomycin-resistant, VanB-type Enterococcus faecalis endocarditis.

D P Nicolau 1, M N Marangos 1, C H Nightingale 1, K B Patel 1, B W Cooper 1, R Quintiliani Jr 1, P Courvalin 1, R Quintiliani 1
PMCID: PMC163056  PMID: 8787879

Abstract

The efficacy of vancomycin (VM) and teicoplanin (TE), alone and in combination with streptomycin (SM), against enterococci that express low-level VanB-type VM resistance was investigated in experimental endocarditis using isogenic strains of Enterococcus faecalis susceptible to glycopeptides and aminoglycosides or inducibly resistant to low levels of VM (MIC = 16 micrograms/ml). VM was significantly less active against the resistant strain than against the susceptible strain, establishing that low-level VanB-type VM resistance can influence therapeutic efficacy. By contrast, TE had equally good activity against both strains. VM or TE combined with SM was synergistic and bactericidal against the resistant strain in vitro. While both combinations were efficient in reducing bacterial density in vivo, TE plus SM was significantly superior to VM plus SM if valve sterilization was considered. These data suggest that despite the presence of low-level VanB-type resistance, combination therapy with a glycopeptide and SM (and presumably other aminoglycosides to which there is not high-level resistance) will nevertheless provide effective bactericidal activity.

Full Text

The Full Text of this article is available as a PDF (240.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arthur M., Courvalin P. Genetics and mechanisms of glycopeptide resistance in enterococci. Antimicrob Agents Chemother. 1993 Aug;37(8):1563–1571. doi: 10.1128/aac.37.8.1563. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Billot-Klein D., Gutmann L., Sablé S., Guittet E., van Heijenoort J. Modification of peptidoglycan precursors is a common feature of the low-level vancomycin-resistant VANB-type Enterococcus D366 and of the naturally glycopeptide-resistant species Lactobacillus casei, Pediococcus pentosaceus, Leuconostoc mesenteroides, and Enterococcus gallinarum. J Bacteriol. 1994 Apr;176(8):2398–2405. doi: 10.1128/jb.176.8.2398-2405.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bush L. M., Calmon J., Cherney C. L., Wendeler M., Pitsakis P., Poupard J., Levison M. E., Johnson C. C. High-level penicillin resistance among isolates of enterococci. Implications for treatment of enterococcal infections. Ann Intern Med. 1989 Apr 1;110(7):515–520. doi: 10.7326/0003-4819-110-7-515. [DOI] [PubMed] [Google Scholar]
  4. Dutka-Malen S., Leclercq R., Coutant V., Duval J., Courvalin P. Phenotypic and genotypic heterogeneity of glycopeptide resistance determinants in gram-positive bacteria. Antimicrob Agents Chemother. 1990 Oct;34(10):1875–1879. doi: 10.1128/aac.34.10.1875. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Entenza J. M., Calandra T., Moosmann Y., Malinverni R., Glauser M. P. Teicoplanin versus vancomycin for prophylaxis of experimental Enterococcus faecalis endocarditis in rats. Antimicrob Agents Chemother. 1992 Jun;36(6):1256–1262. doi: 10.1128/aac.36.6.1256. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Erickson R. C., Hildebrand A. R., Hoffman P. F., Gibson C. B. A sensitive bioassay for teicoplanin in serum in the presence or absence of other antibiotics. Diagn Microbiol Infect Dis. 1989 May-Jun;12(3):235–241. doi: 10.1016/0732-8893(89)90020-5. [DOI] [PubMed] [Google Scholar]
  7. Evers S., Reynolds P. E., Courvalin P. Sequence of the vanB and ddl genes encoding D-alanine:D-lactate and D-alanine:D-alanine ligases in vancomycin-resistant Enterococcus faecalis V583. Gene. 1994 Mar 11;140(1):97–102. doi: 10.1016/0378-1119(94)90737-4. [DOI] [PubMed] [Google Scholar]
  8. Evers S., Sahm D. F., Courvalin P. The vanB gene of vancomycin-resistant Enterococcus faecalis V583 is structurally related to genes encoding D-Ala:D-Ala ligases and glycopeptide-resistance proteins VanA and VanC. Gene. 1993 Feb 14;124(1):143–144. doi: 10.1016/0378-1119(93)90779-3. [DOI] [PubMed] [Google Scholar]
  9. Fantin B., Leclercq R., Arthur M., Duval J., Carbon C. Influence of low-level resistance to vancomycin on efficacy of teicoplanin and vancomycin for treatment of experimental endocarditis due to Enterococcus faecium. Antimicrob Agents Chemother. 1991 Aug;35(8):1570–1575. doi: 10.1128/aac.35.8.1570. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Francioli P., Moreillon P., Glauser M. P. Comparison of single doses of amoxicillin or of amoxicillin-gentamicin for the prevention of endocarditis caused by Streptococcus faecalis and by viridans streptococci. J Infect Dis. 1985 Jul;152(1):83–89. doi: 10.1093/infdis/152.1.83. [DOI] [PubMed] [Google Scholar]
  11. GERACI J. E., MARTIN W. J. Antibiotic therapy of bacterial endocarditis. VI. Subacute enterococcal endocarditis; clinical, pathologic and therapeutic consideration of 33 cases. Circulation. 1954 Aug;10(2):173–194. doi: 10.1161/01.cir.10.2.173. [DOI] [PubMed] [Google Scholar]
  12. Hayden M. K., Trenholme G. M., Schultz J. E., Sahm D. F. In vivo development of teicoplanin resistance in a VanB Enterococcus faecium isolate. J Infect Dis. 1993 May;167(5):1224–1227. doi: 10.1093/infdis/167.5.1224. [DOI] [PubMed] [Google Scholar]
  13. Hellinger W. C., Rouse M. S., Rabadan P. M., Henry N. K., Steckelberg J. M., Wilson W. R. Continuous intravenous versus intermittent ampicillin therapy of experimental endocarditis caused by aminoglycoside-resistant enterococci. Antimicrob Agents Chemother. 1992 Jun;36(6):1272–1275. doi: 10.1128/aac.36.6.1272. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Leclercq R., Bingen E., Su Q. H., Lambert-Zechovski N., Courvalin P., Duval J. Effects of combinations of beta-lactams, daptomycin, gentamicin, and glycopeptides against glycopeptide-resistant enterococci. Antimicrob Agents Chemother. 1991 Jan;35(1):92–98. doi: 10.1128/aac.35.1.92. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Leclercq R., Dutka-Malen S., Brisson-Noël A., Molinas C., Derlot E., Arthur M., Duval J., Courvalin P. Resistance of enterococci to aminoglycosides and glycopeptides. Clin Infect Dis. 1992 Sep;15(3):495–501. doi: 10.1093/clind/15.3.495. [DOI] [PubMed] [Google Scholar]
  16. Leport C., Perronne C., Massip P., Canton P., Leclercq P., Bernard E., Lutun P., Garaud J. J., Vilde J. L. Evaluation of teicoplanin for treatment of endocarditis caused by gram-positive cocci in 20 patients. Antimicrob Agents Chemother. 1989 Jun;33(6):871–876. doi: 10.1128/aac.33.6.871. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Malinverni R., Francioli P. B., Glauser M. P. Comparison of single and multiple doses of prophylactic antibiotics in experimental streptococcal endocarditis. Circulation. 1987 Aug;76(2):376–382. doi: 10.1161/01.cir.76.2.376. [DOI] [PubMed] [Google Scholar]
  18. Murray B. E. The life and times of the Enterococcus. Clin Microbiol Rev. 1990 Jan;3(1):46–65. doi: 10.1128/cmr.3.1.46. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Nachamkin I., Axelrod P., Talbot G. H., Fischer S. H., Wennersten C. B., Moellering R. C., Jr, MacGregor R. R. Multiply high-level-aminoglycoside-resistant enterococci isolated from patients in a university hospital. J Clin Microbiol. 1988 Jul;26(7):1287–1291. doi: 10.1128/jcm.26.7.1287-1291.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Nicolau D. P., Freeman C. D., Nightingale C. H., Coe C. J., Quintiliani R. Minocycline versus vancomycin for treatment of experimental endocarditis caused by oxacillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 1994 Jul;38(7):1515–1518. doi: 10.1128/aac.38.7.1515. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Nicolau D. P., Freeman C. D., Nightingale C. H., Quintiliani R., Coe C. J., Maderazo E. G., Cooper B. W. Reduction of bacterial titers by low-dose aspirin in experimental aortic valve endocarditis. Infect Immun. 1993 Apr;61(4):1593–1595. doi: 10.1128/iai.61.4.1593-1595.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Nicolau D. P., Freeman C. D., Nightingale C. H., Quintiliani R. Pharmacokinetics of minocycline and vancomycin in rabbits. Lab Anim Sci. 1993 Jun;43(3):222–225. [PubMed] [Google Scholar]
  23. Presterl E., Graninger W., Georgopoulos A. The efficacy of teicoplanin in the treatment of endocarditis caused by gram-positive bacteria. J Antimicrob Chemother. 1993 May;31(5):755–766. doi: 10.1093/jac/31.5.755. [DOI] [PubMed] [Google Scholar]
  24. Reynolds P. E. Structure, biochemistry and mechanism of action of glycopeptide antibiotics. Eur J Clin Microbiol Infect Dis. 1989 Nov;8(11):943–950. doi: 10.1007/BF01967563. [DOI] [PubMed] [Google Scholar]
  25. Sahm D. F., Kissinger J., Gilmore M. S., Murray P. R., Mulder R., Solliday J., Clarke B. In vitro susceptibility studies of vancomycin-resistant Enterococcus faecalis. Antimicrob Agents Chemother. 1989 Sep;33(9):1588–1591. doi: 10.1128/aac.33.9.1588. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Sahm D. F., Olsen L. In vitro detection of enterococcal vancomycin resistance. Antimicrob Agents Chemother. 1990 Sep;34(9):1846–1848. doi: 10.1128/aac.34.9.1846. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Schaberg D. R., Culver D. H., Gaynes R. P. Major trends in the microbial etiology of nosocomial infection. Am J Med. 1991 Sep 16;91(3B):72S–75S. doi: 10.1016/0002-9343(91)90346-y. [DOI] [PubMed] [Google Scholar]
  28. Spiegel C. A., Huycke M. Endocarditis due to streptomycin-susceptible Enterococcus faecalis with high-level gentamicin resistance. Arch Intern Med. 1989 Aug;149(8):1873–1875. [PubMed] [Google Scholar]
  29. Swenson J. M., Ferraro M. J., Sahm D. F., Charache P., Tenover F. C. New vancomycin disk diffusion breakpoints for enterococci. The National Committee for Clinical Laboratory Standards Working Group on Enterococci. J Clin Microbiol. 1992 Oct;30(10):2525–2528. doi: 10.1128/jcm.30.10.2525-2528.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Swenson J. M., Hill B. C., Thornsberry C. Problems with the disk diffusion test for detection of vancomycin resistance in enterococci. J Clin Microbiol. 1989 Sep;27(9):2140–2142. doi: 10.1128/jcm.27.9.2140-2142.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Thauvin C., Eliopoulos G. M., Willey S., Wennersten C., Moellering R. C., Jr Continuous-infusion ampicillin therapy of enterococcal endocarditis in rats. Antimicrob Agents Chemother. 1987 Feb;31(2):139–143. doi: 10.1128/aac.31.2.139. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Tight R. R. Ampicillin therapy of experimental enterococcal endocarditis. Antimicrob Agents Chemother. 1980 Aug;18(2):307–310. doi: 10.1128/aac.18.2.307. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Willey B. M., Kreiswirth B. N., Simor A. E., Willaims G., Scriver S. R., Phillips A., Low D. E. Detection of vancomycin resistance in Enterococcus species. J Clin Microbiol. 1992 Jul;30(7):1621–1624. doi: 10.1128/jcm.30.7.1621-1624.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Williamson R., Al-Obeid S., Shlaes J. H., Goldstein F. W., Shlaes D. M. Inducible resistance to vancomycin in Enterococcus faecium D366. J Infect Dis. 1989 Jun;159(6):1095–1104. doi: 10.1093/infdis/159.6.1095. [DOI] [PubMed] [Google Scholar]
  35. Wilson A. P., Grüneberg R. N., Neu H. Dosage recommendations for teicoplanin. J Antimicrob Chemother. 1993 Dec;32(6):792–796. doi: 10.1093/jac/32.6.792. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES